Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gene clue may explain why some women are more vulnerable to HIV

NCT ID NCT01952587

Knowledge-focused Sponsor: ANRS, Emerging Infectious Diseases Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at a genetic variation in the TLR7 gene, which helps the immune system detect viruses like HIV-1. Researchers compared 90 women—some with HIV and some without—to see if this gene difference is more common in infected women. The goal was to understand how this variation might affect the body's first line of defense against HIV.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could point toward new ways to understand or reduce HIV infection risk in women based on genetics.
What could go wrong
This is a small, completed observational study, not a treatment trial. It only looks at a genetic factor and does not test any therapy, so it may not lead to direct medical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

90 people

The number who actually took part.

Start date

Nov 2013

Finished

Jun 2015

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Caucasian Female 2. HIV-1 infection (ELISA and western-blot tests) 3. HIV-infection through the sexual route before 50 years-old 4. Continuous antiretroviral therapy for more than 6 months 5. Plasma HIV-1 RNA \<50 copies/ml in the last 6 months 6. Age \>18-year old 7. Health insurance 8. Informed consent Exclusion Criteria: 1. HIV-infection through vertical or parenteral routes 2. Chronic infectious disease, notably HCV infection (hepatitis C virus) 3. Acute infectious disease 4. Auto-immune disease 5. Absence of social security (health insurance) 6. Pregnant or breastfeeding woman 7. Incapable adult

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV infection

Contacts and locations

Locations

  • Purpan Hospital

    Toulouse, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.